Orlando, FL-based nScrypt has partnered with the U.S. Military, the Uniformed Services University 4D Bio3 Program, RoosterBio, Inc, and The Geneva Foundation to move bioprinting out of sterile biology laboratories to forward-deployed military positions. For this project, nScrypt has customized its BioAssembly Tool (BAT) bioprinter, which won the 2003 R&D 100 award and is scheduled to travel to the International Space Station in July 2019, and created a light weight and ruggedized model, shrouding it in a protective local environment for bioprinting in challenging conditions. The research team will ship the ruggedized bioprinter (also called an “austere bioprinter”), and RoosterBio’s Ready To Print (RTP) human bone marrow derived mesenchymal stem/stromal cells (MSCs) to an undisclosed, forward-deployed location for ten (10) weeks of bioprinting and experimentation in a desert environment, led by LTC Jason Barnhill of the United States Military Academy’s Department of Chemistry and Life Science (West Point). The team intends to create a number of experimental prints, including plastic medical models, MSC tissue constructs, and next-gen wound bandages.
This project is a step towards bringing next-generation critical care close to the warfighter. Bioprinting a variety of wound-healing biologics, bandages, stents, and bandage/biosensors, on demand and at or near the point-of-care, is an example that is expected to improve healing and survival rates of the warfighter. Point-of-care bioprinting is also expected to provide significant advantages in soldier care and military applications, reducing expensive and wasteful logistics, warehousing, refrigeration, and shipping. Bioprinting only what the soldier needs, where it is needed, and when it is needed, is expected to improve outcomes and reduce overall costs of advanced medicine for our warfighter.
About nScrypt: Founded in 2002 and headquartered in Orlando, Florida, nScrypt designs and manufactures award-winning, next-generation, high-precision Micro-Dispensing and Direct Digital Manufacturing equipment and solutions for industrial applications, with unmatched accuracy and flexibility. Serving the printed electronics, electronics packaging, solar cell metallization, communications, printed antenna, life science, chemical/pharmaceutical, defense, space, and 3D printing industries, our equipment and solutions are widely used by the military, academic and research institutes, government agencies and national labs, and private companies. nScrypt is a 2002 spin out from Sciperio Inc., a research and development think tank specializing in cross-disciplinary solutions. The nScrypt BAT Series Bioprinter, which won the R&D 100 award in 2003, will travel to the International Space Station in 2019, in a joint program with Techshot. nScrypt Cyberfacturing Center is our direct digital contract design and manufacturing service.
About The Geneva Foundation: The Geneva Foundation is a 501(c)3 non-profit organization that advances military medicine through innovative scientific research, exceptional program management, and a dedication to U.S. service members and veterans, their families, and the global community. Geneva is proud to have over 25 years of experience in delivering full spectrum scientific, technical, and program management expertise in the areas of federal grants, federal contracts, industry sponsored clinical trials, and educational services. www.genevaUSA.org
About RoosterBio, Inc: RoosterBio, Inc. is a privately held cell manufacturing platform technology company focused on accelerating the development of a sustainable regenerative medicine industry, one customer at a time. RoosterBio’s products are high-volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. RoosterBio has simplified and standardized how stem cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers. RoosterBio’s innovative products are ushering in a new era of productivity and standardization into the field, accelerating the road to discovery in Regenerative Medicine.
ViewMedia Info
To request an interview, contact our Media Relations team.